Baird Medical Investment Holdings Ltd
No SEC Form 4 filings for $BDMD in the last 30 days.
See all $BDMD insider activity →Baird Medical Investment Holdings Ltd (BDMD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Baird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026 Revenue increase driven by significant growth in the United States and other strategic markets NEW YORK, September 3, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment
Baird Medical Investment Holdings (NASDAQ: BDMD) said it signed a strategic cooperation agreement with Alpmed, a China-based IRE technology company, to develop and commercialize next-generation irreversible electroporation ablation. The firms plan a U.S. FDA 510(k) submission by end-2026 and potential clearance in 2027 for a soft-tissue tumor device.
Over the past 7 days, alphai's AI scored 1 news story mentioning BDMD (Baird Medical Investment Holdings Ltd). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent BDMD coverage spans earnings and technology.
Positive earnings surprise with revenue growth and profitability turnaround.
The deal creates a concrete regulatory timeline and expands BDMD beyond its MWA base into IRE, potentially improving medium-term growth optionality.
alphai scores every news story that mentions BDMD with an AI model for sentiment and relevance, and aggregates insider trades from Baird Medical Investment Holdings Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Baird Medical Investment Holdings Ltd (BDMD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Baird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026 Revenue increase driven by significant growth in the United States and other strategic markets NEW YORK, September 3, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment
2 min readBaird Medical Investment Holdings (NASDAQ: BDMD) said it signed a strategic cooperation agreement with Alpmed, a China-based IRE technology company, to develop and commercialize next-generation irreversible electroporation ablation. The firms plan a U.S. FDA 510(k) submission by end-2026 and potential clearance in 2027 for a soft-tissue tumor device.
3 min read